Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 119   

Articles published

JNJ 106.59 +0.05 (0.05%)
price chart
Johnson & Johnson Buying Alios for $1.75B
Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases.
Johnson & Johnson to Buy Biotech Company Alios BioPharma  New York Times
What Johnson & Johnson's Alios Acquisition Means for Gilead Sciences  Barron's (blog)
Related articles »  
Johnson & Johnson buying Alios BioPharma for $1.75 billion
NEW BRUNSWICK, N.J. - Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion.
Johnson & Johnson (JNJ) to Acquire Alios BioPharma
On Tuesday, Johnson & Johnson (JNJ - Analyst Report) announced that the company had plans to add Alios BioPharma, a private biotechnology company focused on treating viral diseases, to its assets.
Johnson & Johnson to buy private drug developer for $1.75 billion
(Reuters) - Johnson & Johnson agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a respiratory viral infection for which there is no approved treatment.
UPDATE 2-Johnson & Johnson to buy private drug developer for $1.75 bln
(Adds J&J comment, deal advisers, updates share price). By Vidya L Nathan. Sept 30 (Reuters) - Johnson & Johnson agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a common respiratory viral ...
Johnson & Johnson to Quicken Development of Ebola Virus Vaccine
"The decision to accelerate the program is based on the fact that it is such a catastrophic situation in West Africa," said Dr.
Johnson & Johnson Pushes Ahead With Ebola Vaccine  NPR (blog)
Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate ...  MarketWatch
Related articles »  
Cravath Helps Johnson & Johnson Bag Another Pharma Firm
Drug and pharmaceutical giant Johnson & Johnson has agreed to pay $1.75 billion in cash to acquire Alios BioPharma, a private biotechnology company developing a medicine to combat a serious childhood respiratory infection for which there is no current ...
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson Johnson & Johnson (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call ...
Related articles »  
Johnson & Johnson Is The Most Attractive Mega-Cap Pharma Stock For Income ...
This article compares four mega-cap pharmaceutical stocks with dividend yields above 2% and market caps above $150 billion. Johnson & Johnson's dividend growth history, conservative payout ratio and projected future growth are impressive.
Johnson & Johnson Hoping Brand Won't Be Tarnished If They Dip Into Lethal ...
NEW BRUNSWICK, NJ�Saying that the company could cash in big time on the opportunity, Johnson & Johnson CEO Alex Gorsky expressed his hope to reporters Friday that the pharmaceutical manufacturer's family-friendly image would not be tarnished if it ...